Use of phage display technology to investigate allergen-antibody interactions

• Published in: Journal of allergy and clinical immunology 2000-06, Vol.105 (6), p.1085-1092
• Main Authors: Davies, Janet M., O’Hehir, Robyn E., Suphioglu, Cenk
• Format: Article
• Language: English
• Subjects: allergen; Allergens - immunology; Antigen-Antibody Reactions; Bacteriophage M13 - physiology; Bacteriophages - genetics; Biological and medical sciences; Biotechnology - methods; Data Display; epitope; FAb; Gene Library; Humans; IgE; Immunological methods for diagnosis and exploration; Immunopathology; Medical sciences; Other methods; Phage display
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1067/mai.2000.107040

Phage display is an advanced technology that can be used to characterize the interactions of antibody with antigen at the molecular level. It provides valuable data when applied to the investigation of IgE interaction with allergens. The aim of this rostrum article is to provide an explanation of the potential of phage display for increasing the understanding of allergen-IgE interaction, the discovery of diagnostic reagents, and the development of novel therapeutics for the treatment of allergic disease. The significance of initial studies that have applied phage display technology in allergy research will be highlighted. Phage display has been used to clone human IgE to timothy grass pollen allergen Phl p 5, to characterize the epitopes for murine and human antibodies to a birch pollen allergen Bet v 1, and to elucidate the epitopes of a murine mAb to the house dust mite allergen Der p 1. The technology has identified peptides that functionally mimic sites of human IgE constant domains and that were used to raise antiserum for blocking binding of IgE to the FcϵRI on basophils and subsequent release of histamine. Phage display has also been used to characterize novel peanut and fungal allergens. The method has been used to increase our understanding of the molecular basis of allergen-IgE interactions and to develop clinically relevant reagents with the pharmacologic potential to block the effector phase of allergic reactions. Many advances from these early studies are likely as phage display technology evolves and allergists gain expertise in its research applications. (J Allergy Clin Immunol 2000;105:1085-92.)